These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29685646)

  • 1. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
    Pal SK; Bergerot P; Dizman N; Bergerot C; Adashek J; Madison R; Chung JH; Ali SM; Jones JO; Salgia R
    Eur Urol; 2018 Jul; 74(1):124-128. PubMed ID: 29685646
    [No Abstract]   [Full Text] [Related]  

  • 2. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
    Kathuria-Prakash N; Lopez LP; Raman S; Ye H; Anaokar J; Sisk A; Pantuck AJ; Drakaki A
    JCO Precis Oncol; 2024 Jun; 8():e2400154. PubMed ID: 38885453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
    Tamiya A; Shimizu S; Atagi S
    J Thorac Oncol; 2015 Aug; 10(8):e74. PubMed ID: 26200283
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
    Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
    Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V; Ou SH
    Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
    Ajimizu H; Kim YH; Mishima M
    Med Oncol; 2015 Feb; 32(2):477. PubMed ID: 25556163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
    Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alectinib-responsive infantile anaplastic ganglioglioma with a novel VCL-ALK gene fusion.
    Yamamoto S; Koga Y; Ono H; Goto H; Hata N; Yamamoto H; Suzuki SO; Sakai Y; Iwaki T; Ohga S
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29122. PubMed ID: 34019333
    [No Abstract]   [Full Text] [Related]  

  • 15. Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy.
    Grubb WR; Machtay M; Dowlati A; Biswas T
    Pract Radiat Oncol; 2019 Mar; 9(2):e129-e133. PubMed ID: 30665865
    [No Abstract]   [Full Text] [Related]  

  • 16. Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion.
    Velcheti V; Ahluwalia M
    J Thorac Oncol; 2017 Jul; 12(7):e98-e99. PubMed ID: 28629549
    [No Abstract]   [Full Text] [Related]  

  • 17. Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma.
    Heath JA; Campbell MA; Thomas A; Solomon B
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27055. PubMed ID: 29603581
    [No Abstract]   [Full Text] [Related]  

  • 18. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M; Altavilla G; Rosell R
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K
    Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V; Pérol M
    Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.